Affibody AB Reports New Phase 3 HS Subgroup and IHS4 Efficacy Data
Affibody reported new analyses from its Phase 3 HS study showing consistent izokibep efficacy across patient subgroups and higher IHS4-55/75/90/100 rates vs placebo at week 12, with sustained responses to week 32.Material DetailsContext by AI AnalystThis is late-stage confirmation adding subgroup a…